{"id":30819,"date":"2025-01-17T10:00:00","date_gmt":"2025-01-17T04:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30819"},"modified":"2025-01-17T14:39:49","modified_gmt":"2025-01-17T09:09:49","slug":"acute-kidney-injury-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape","title":{"rendered":"Everything You Need to Know About Acute Kidney Injury"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2cb995eb1c5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2cb995eb1c5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#What_is_Acute_Kidney_Injury\" >What is Acute Kidney Injury?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Symptoms_of_Acute_Kidney_Injury\" >Symptoms of Acute Kidney Injury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Causes_of_Acute_Kidney_Injury\" >Causes of Acute Kidney Injury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Diagnosis_of_Acute_Kidney_Injury\" >Diagnosis of Acute Kidney Injury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Stages_of_Acute_Kidney_Injury\" >Stages of Acute Kidney Injury<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Incidence_and_Impact_of_Acute_Kidney_Injury\" >Incidence and Impact of Acute Kidney Injury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Treatment_for_Acute_Kidney_Injury\" >Treatment for Acute Kidney Injury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Acute_Kidney_Injury_Treatment_Market_Outlook\" >Acute Kidney Injury Treatment Market Outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Acute_Kidney_Injury_Treatment_Market_Trends_and_Insights\" >Acute Kidney Injury Treatment Market Trends and Insights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Acute_Kidney_Injury_Treatment_Market_Barriers_and_Drivers\" >Acute Kidney Injury Treatment Market Barriers and Drivers<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Acute Kidney Injury (AKI) is a significant medical condition that affects millions of individuals worldwide each year. It is a rapidly progressive condition that requires timely diagnosis and treatment to prevent severe complications or long-term consequences. AKI is particularly prevalent in hospitalized patients, especially those receiving critical care, highlighting its global importance in healthcare settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Acute_Kidney_Injury\"><\/span>What is Acute Kidney Injury?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Acute Kidney Injury (AKI) is a rapidly progressive condition that leads to a sudden decline in kidney function, typically over hours or days. It is characterized by the inability of the kidneys to effectively filter waste, manage fluid balance, and regulate electrolytes, which can result in serious complications such as electrolyte imbalances, fluid overload, and accumulation of toxins in the body. The causes of AKI are varied, including prerenal factors like decreased blood flow to the kidneys, intrinsic kidney damage, and postrenal obstruction in the urinary tract. <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\">Acute Kidney Injury<\/a> can lead to permanent kidney damage if left untreated, but in many cases, the kidneys can recover with appropriate treatment.<\/p>\n\n\n\n<p>Annually, AKI affects millions of people worldwide. Approximately <strong>13 million cases<\/strong> of AKI occur globally, and although infections are a leading cause, they are more prevalent in low- and middle-income countries. In more developed nations, AKI is a common complication in hospitalized patients, especially in those in critical care. AKI can be classified into three stages, with Stage I being the mildest form and Stage III the most severe, often requiring acute kidney injury interventions like dialysis or renal replacement therapy (RRT). Treatment is mostly supportive, focusing on maintaining fluid and electrolyte balance, and preventing further kidney damage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Symptoms_of_Acute_Kidney_Injury\"><\/span>Symptoms of Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The symptoms of AKI vary depending on the severity and the underlying cause. Early symptoms may be subtle, making it difficult to detect. However, as the condition progresses, symptoms become more noticeable and can include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Decreased Urine Output<\/strong>: A noticeable drop in the amount of urine produced.<\/li>\n\n\n\n<li><strong>Swelling<\/strong>: Fluid retention leads to swelling in the legs, ankles, or face.<\/li>\n\n\n\n<li><strong>Fatigue<\/strong>: Feeling unusually tired or lethargic.<\/li>\n\n\n\n<li><strong>Shortness of Breath<\/strong>: Due to fluid accumulation in the lungs.<\/li>\n\n\n\n<li><strong>Confusion<\/strong>: A result of the buildup of waste products in the blood.<\/li>\n\n\n\n<li><strong>Nausea and Vomiting<\/strong>: Often caused by an imbalance in electrolytes.<\/li>\n\n\n\n<li><strong>Chest Pain<\/strong>: This can occur if the kidneys fail to regulate fluid and electrolytes properly.<\/li>\n<\/ul>\n\n\n\n<p>It is important to note that in some cases, AKI can be asymptomatic in its early stages. As a result, regular monitoring of kidney function is critical, particularly for patients at high risk.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Causes_of_Acute_Kidney_Injury\"><\/span>Causes of Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Acute Kidney Injury can result from various causes, which can be broadly classified into three categories:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Prerenal Causes<\/strong>: These occur due to decreased blood flow to the kidneys, which can result from conditions like dehydration, heart failure, or severe blood loss.\n<ul class=\"wp-block-list\">\n<li><strong>Examples<\/strong>: Hypovolemia, hypotension, heart failure, sepsis.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Intrinsic (Renal) Causes<\/strong>: Damage to the kidney tissues, often caused by infections, toxins, or ischemia.\n<ul class=\"wp-block-list\">\n<li><strong>Examples<\/strong>: Acute tubular necrosis (ATN), glomerulonephritis, interstitial nephritis.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Postrenal Causes<\/strong>: These occur when there is an obstruction in the urinary tract that prevents the kidneys from filtering waste.\n<ul class=\"wp-block-list\">\n<li><strong>Examples<\/strong>: Kidney stones, bladder obstruction, or tumors.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<p>While infections are a common cause of AKI globally, it is important to note that infection-associated AKI is more prevalent in low- and middle-income countries. The risk of AKI is higher in individuals with certain underlying conditions like <strong>diabetes<\/strong>, <strong>hypertension<\/strong>, and <strong>heart failure<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnosis_of_Acute_Kidney_Injury\"><\/span>Diagnosis of Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Diagnosis of AKI typically involves blood tests, urine tests, and imaging studies. The main diagnostic criteria for AKI include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Serum Creatinine Levels<\/strong>: A sudden increase in serum creatinine by 0.3 mg\/dL or more within 48 hours, or a 50% increase from baseline, indicates AKI.<\/li>\n\n\n\n<li><strong>Urine Output<\/strong>: A reduction in urine output to less than 0.5 mL\/kg\/h for more than 6 hours suggests AKI.<\/li>\n\n\n\n<li><strong>Urine Tests<\/strong>: To detect protein, blood, or other abnormalities that could indicate kidney damage.<\/li>\n\n\n\n<li><strong>Imaging Studies<\/strong>: Ultrasound or CT scans to detect any physical obstruction or structural abnormalities in the kidneys.<\/li>\n<\/ul>\n\n\n\n<p>Early-stage AKI may be asymptomatic, as clinical signs are contingent on the extent of renal impairment. Prioritizing the integration of kidney injury markers into clinical practice, as opposed to the current function-based approach, remains crucial for accurate diagnosis.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Stages_of_Acute_Kidney_Injury\"><\/span>Stages of Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AKI is classified into three stages based on severity, as defined by changes in serum creatinine levels and urine output:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Stage I<\/strong>: A slight increase in serum creatinine (1.5-1.9 times baseline) or a decrease in urine output to less than 0.5 mL\/kg\/h for 6-12 hours.<\/li>\n\n\n\n<li><strong>Stage II<\/strong>: A moderate increase in serum creatinine (2-2.9 times baseline) or a decrease in urine output to less than 0.5 mL\/kg\/h for more than 12 hours.<\/li>\n\n\n\n<li><strong>Stage III<\/strong>: A severe increase in serum creatinine (3 times baseline or \u22654.0 mg\/dL) or a decrease in urine output to less than 0.3 mL\/kg\/h for more than 24 hours, or the need for kidney replacement therapy.<\/li>\n<\/ol>\n\n\n\n<p>In the U.S., <strong>Stage I<\/strong> comprised the highest number of AKI cases in <strong>2023<\/strong>, with nearly <strong>3.79 million<\/strong> cases, followed by <strong>Stage II<\/strong>. <strong>Stage III AKI<\/strong>, which often requires <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-renal-failure-arf-acute-kidney-injury-market\"><strong>acute renal failure treatment<\/strong><\/a>, accounted for around <strong>15%<\/strong> of cases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incidence-and-impact-of-acute-kidney-injury\"><span class=\"ez-toc-section\" id=\"Incidence_and_Impact_of_Acute_Kidney_Injury\"><\/span>Incidence and Impact of Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Acute Kidney Injury affects millions of individuals worldwide. Globally, there are an estimated <strong>13.3 million cases<\/strong> of AKI annually. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-epidemiology-forecast\">incidence of Acute Kidney Injury<\/a> is higher in <strong>low- and middle-income countries<\/strong>, where infection-associated AKI is prevalent. The condition can occur at any age but is particularly common in elderly individuals, particularly those with multiple underlying health conditions. <strong>In the U.S.<\/strong>, nearly <strong>128K patients<\/strong> were admitted to the University of Florida Health, with <strong>20%<\/strong> of encounters involving AKI.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"394\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-1024x394.png\" alt=\"Acute-Kidney-Injury-Market-Key-Insights\" class=\"wp-image-30810\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-1024x394.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-768x295.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-1536x591.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16100826\/Acute-Kidney-Injury-Market-Key-Insights-2048x788.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>According to <strong>DelveInsight\u2019s analysis<\/strong>, in <strong>2023<\/strong>, the U.S. saw nearly <strong>5.74 million<\/strong> mortality-adjusted incident cases of AKI in hospitalized patients. The overall incidence of AKI in hospitalized patients in the U.S. is around <strong>9.57 million<\/strong>. In <strong>Germany<\/strong>, the highest number of AKI cases occurred in hospitalized patients, while <strong>France<\/strong> followed with a smaller share. In <strong>Japan<\/strong>, the age group of <strong>\u2265 80 years<\/strong> saw the highest number of AKI cases, followed by the <strong>60-79 years<\/strong> age group. There is an unmet need to enhance the follow-up of individuals who have experienced in-hospital AKI episodes, as well as to identify those at risk of recurrent AKI or developing CKD.&nbsp;<\/p>\n\n\n\n<p>which often requires <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-renal-failure-arf-acute-kidney-injury-market\" class=\"ek-link\"><strong>acute renal failure treatment<\/strong><\/a>, accounted for around <strong>15%<\/strong> of cases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-for-acute-kidney-injury\"><span class=\"ez-toc-section\" id=\"Treatment_for_Acute_Kidney_Injury\"><\/span>Treatment for Acute Kidney Injury<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, there are <em>no specific pharmacotherapies approved <\/em>for <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-pipeline-insight\">AKI treatment<\/a>. Management of acute kidney failure is focused chiefly on <strong>supportive care<\/strong>, such as fluid resuscitation, electrolyte correction, and renal replacement therapy (RRT). RRT is necessary in severe cases, especially for those in <strong>Stage III<\/strong> of AKI. This therapy includes <strong>hemodialysis<\/strong>, <strong>peritoneal dialysis<\/strong>, and <strong>continuous renal replacement therapy (CRRT)<\/strong>.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"428\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-1024x428.png\" alt=\"\" class=\"wp-image-30812\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-1024x428.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-300x125.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-150x63.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-768x321.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-1536x641.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16101109\/Emerging-Therapies-for-Acute-Kidney-Injury-2048x855.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Apart from RRT, various <strong>off-label acute kidney injury medications<\/strong> are commonly used to manage AKI, including <strong>ACE inhibitors<\/strong>, <strong>ARBs<\/strong>, <strong>diuretics<\/strong>, and <strong>NSAIDs<\/strong>. However, these drugs only manage symptoms and are not targeted treatments for AKI itself. Several promising therapies are developing in the <a href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-pipeline\">acute kidney injury pipeline<\/a>, including <strong>RBT-1<\/strong>, <strong>Ilofotase alfa<\/strong>, and <strong>bRESCAP<\/strong>, which focus on mitochondrial function, reducing oxidative stress, and improving kidney recovery after injury. Furthermore, In January 2024, Renibus Therapeutics announced the publication of results from<strong> the Phase II Study evaluating RBT-1 <\/strong>as a preconditioning agent to reduce post-operative complications following cardiothoracic surgery. Also, In December 2023, SeaStar Medical announced enrollment of patients in the <strong>NEUTRALIZE-AKI pivotal clinical trial<\/strong> of its cell-directed <strong>Selective Cytopheretic Device (SCD)<\/strong> extracorporeal therapy in critically ill adults with AKI requiring continuous kidney replacement therapy (CKRT).<\/p>\n\n\n\n<p>As of now, these therapies are in various stages of clinical development and hold promise for the future of AKI management.&nbsp;<\/p>\n\n\n\n<p><strong><em>To learn more about breakthrough therapies shaping the future of acute kidney injury treatment, <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/breakthrough-therapies-acute-kidney-injury-treatment\"><strong><em>click here!\u00a0<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acute_Kidney_Injury_Treatment_Market_Outlook\"><\/span>Acute Kidney Injury Treatment Market Outlook<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\">market for AKI treatment<\/a> is expected to grow significantly due to the increasing incidence of the disease and the evolving landscape of therapeutic options. According to DelveInsight, the AKI market was valued at <strong>USD 6.23 billion<\/strong> in 2022 across the <strong>7MM<\/strong> and is expected to grow steadily during the forecast period (2024-2034). In the <strong>7MM<\/strong>, the market is projected to grow at a <strong>CAGR of 4.1%<\/strong> from 2024 to 2034, with the <strong>U.S.<\/strong> being the largest contributor.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acute_Kidney_Injury_Treatment_Market_Trends_and_Insights\"><\/span>Acute Kidney Injury Treatment Market Trends and Insights<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The market is driven by the increasing number of patients requiring <strong>renal replacement therapy (RRT) and off-label drugs, which include various classes such as <em>ACE inhibitors, ARBs, Diuretics, and NSAIDs<\/em><\/strong>. These drugs are currently the primary form of treatment for severe AKI. With an aging population, rising rates of <strong>chronic diseases<\/strong> such as <strong>hypertension<\/strong>, <strong>diabetes<\/strong>, and <strong>heart failure<\/strong>, and increased recognition of AKI as a critical hospital-acquired condition, the demand for AKI treatments is set to grow.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"396\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1024x396.png\" alt=\"\" class=\"wp-image-30802\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1024x396.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-300x116.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-768x297.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1536x595.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-2048x793.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Dive into <a href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-market\">our tailored blog<\/a> to uncover the future of AKI treatment landscape\u2014breakthrough therapies, emerging trends, and untapped opportunities<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acute_Kidney_Injury_Treatment_Market_Barriers_and_Drivers\"><\/span>Acute Kidney Injury Treatment Market Barriers and Drivers<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Acute Kidney Injury (AKI) remains a major healthcare challenge due to its sudden onset and severe consequences, including kidney failure and prolonged hospital stays. As healthcare systems grapple with the rising incidence of AKI, the market for treatments is evolving, driven by advancements in preventive care and the need for effective therapeutic options. However, significant barriers also hinder the development and availability of treatments, making AKI a critical area for innovation.<\/p>\n\n\n\n<p><strong>Market Drivers:<\/strong><\/p>\n\n\n\n<p>The AKI market is driven by the increasing focus on <strong>prophylactic treatments<\/strong>, which aim to prevent AKI in high-risk patients. These treatments can reduce the incidence of AKI, improving patient outcomes and lowering healthcare costs by avoiding expensive interventions like dialysis. This preventive approach is a major opportunity for healthcare systems. In addition, the <strong>advancement of biomarkers<\/strong> for AKI has the potential to accelerate drug development. By identifying specific biomarkers and combining them with machine learning models, clinicians can more accurately target at-risk patients, leading to earlier interventions and more effective therapies. This personalized approach to treatment is set to transform the AKI market.<\/p>\n\n\n\n<p>Furthermore, the rising prevalence of <strong>risk factors<\/strong> such as <strong>diabetes<\/strong>, <strong>heart failure<\/strong>, and <strong>hypertension<\/strong> contributes to the growing demand for AKI treatments. As these conditions increase globally, more patients are at risk for AKI, creating a significant market opportunity. Researchers are also focusing on identifying <strong>AKI sub-phenotypes<\/strong> and developing treatments tailored to these groups, which may help address the critical unmet needs in AKI therapy.<\/p>\n\n\n\n<p><strong>Market Barriers:<\/strong><\/p>\n\n\n\n<p>Despite these opportunities, the AKI market faces significant barriers, with <strong>high trial failure rates<\/strong> being a primary challenge. Many promising drug candidates for AKI have failed in clinical trials, such as the <strong>Phase II AKITA trial of RMC-035<\/strong> and the <strong>Phase III REVIVAL trial of ilofotase alfa<\/strong>. These setbacks slow progress in developing effective treatments. Currently, <strong>dialysis<\/strong> and <strong>supportive care<\/strong> are the only available options, neither of which address the underlying causes of AKI or prevent further kidney damage. This gap in curative therapies remains a critical unmet need.<\/p>\n\n\n\n<p>Additionally, the <strong>complexity of managing AKI<\/strong> due to its varied causes and presentations makes it difficult to find one-size-fits-all treatments. AKI can be triggered by conditions like infections, heart failure, or diabetes, complicating diagnosis and treatment. The <strong>decline in the number of acute care beds<\/strong> is also a growing concern, as fewer specialized kidney units are available to treat AKI patients. This shortage strains healthcare systems, leading to delayed treatment and poorer outcomes. Addressing these challenges will be key to improving the AKI treatment landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Acute Kidney Injury represents a formidable challenge in global healthcare, <strong>impacting millions annually and posing significant consequences<\/strong> for patients and healthcare systems alike. While the absence of targeted pharmacological therapies highlights a critical unmet need, advancements in <strong>acute kidney injury treatments<\/strong> and innovations in care are paving the way for a transformative future.<\/p>\n\n\n\n<p>Today, the cornerstone of AKI management includes early diagnosis, meticulous fluid management, and <strong>treatment for AKI<\/strong> through renal replacement therapies. However, the landscape is shifting with the development of novel <strong>acute kidney injury medications<\/strong>, advanced diagnostics, and personalized strategies to enhance outcomes. Emerging biomarkers and prophylactic approaches are redefining how we approach the <strong>treatment of AKI<\/strong>, offering new avenues for intervention and improved patient care.<\/p>\n\n\n\n<p>As the healthcare industry evolves, integrating cutting-edge technologies and a deeper understanding of disease pathways will be pivotal in revolutionizing <strong>acute kidney injury treatment<\/strong>. From mitigating risks in high-burden scenarios to enhancing recovery outcomes, the future of AKI management promises innovation, precision, and resilience. The journey to addressing this pressing healthcare challenge is well underway, offering hope and a brighter outlook for patients worldwide.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1024x194.png\" alt=\"Acute Kidney Injury Market Outlook\" class=\"wp-image-30804\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Acute Kidney Injury (AKI) is a significant medical condition that affects millions of individuals worldwide each year. It is a rapidly progressive condition that requires timely diagnosis and treatment to prevent severe complications or long-term consequences. AKI is particularly prevalent in hospitalized patients, especially those receiving critical care, highlighting its global importance in healthcare settings. [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30820,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[12851,18322,12850,12852,12853,15874,15876,18323,165,21841,21551,204,812,704,635,18938,21219,4044,22421],"industry":[17225],"therapeutic_areas":[17230],"class_list":["post-30819","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-acute-kidney-injury","tag-acute-kidney-injury-incidence","tag-acute-kidney-injury-market","tag-acute-kidney-injury-market-pipeline","tag-acute-kidney-injury-market-treatment","tag-acute-kidney-injury-pipeline","tag-acute-kidney-injury-therapies","tag-acute-kidney-injury-treatment-market","tag-chronic-diseases","tag-continuous-renal-replacement-therapy","tag-continuous-renal-replacement-therapy-machines","tag-delveinsight","tag-diabetes","tag-fda","tag-heart-failure","tag-hemodialysis","tag-hemodialysis-machines","tag-hypertension","tag-peritoneal-dialysis","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acute Kidney Injury: A Growing Concern in Healthcare<\/title>\n<meta name=\"description\" content=\"Learn about Acute Kidney Injury, its causes, symptoms, stages, and treatment options, including emerging therapies and market trends.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acute Kidney Injury: A Growing Concern in Healthcare\" \/>\n<meta property=\"og:description\" content=\"Learn about Acute Kidney Injury, its causes, symptoms, stages, and treatment options, including emerging therapies and market trends.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-17T04:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-17T09:09:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acute Kidney Injury: A Growing Concern in Healthcare","description":"Learn about Acute Kidney Injury, its causes, symptoms, stages, and treatment options, including emerging therapies and market trends.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Acute Kidney Injury: A Growing Concern in Healthcare","og_description":"Learn about Acute Kidney Injury, its causes, symptoms, stages, and treatment options, including emerging therapies and market trends.","og_url":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-17T04:30:00+00:00","article_modified_time":"2025-01-17T09:09:49+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape","name":"Acute Kidney Injury: A Growing Concern in Healthcare","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury.png","datePublished":"2025-01-17T04:30:00+00:00","dateModified":"2025-01-17T09:09:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Learn about Acute Kidney Injury, its causes, symptoms, stages, and treatment options, including emerging therapies and market trends.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury.png","width":466,"height":284,"caption":"Everything You Need to Know About Acute Kidney Injury"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16220239\/Everything-You-Need-to-Know-About-Acute-Kidney-Injury-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Incidence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Market Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Market Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Continuous Renal Replacement Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Continuous Renal Replacement Therapy Machines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Heart failure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemodialysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemodialysis Machines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">peritoneal dialysis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Kidney Injury<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Incidence<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Market<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Market Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Market Treatment<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Therapies<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">chronic diseases<\/span>","<span class=\"advgb-post-tax-term\">Continuous Renal Replacement Therapy<\/span>","<span class=\"advgb-post-tax-term\">Continuous Renal Replacement Therapy Machines<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Heart failure<\/span>","<span class=\"advgb-post-tax-term\">Hemodialysis<\/span>","<span class=\"advgb-post-tax-term\">Hemodialysis Machines<\/span>","<span class=\"advgb-post-tax-term\">hypertension<\/span>","<span class=\"advgb-post-tax-term\">peritoneal dialysis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 17, 2025","modified":"Updated on Jan 17, 2025"},"absolute_dates_time":{"created":"Posted on Jan 17, 2025 10:00 am","modified":"Updated on Jan 17, 2025 2:39 pm"},"featured_img_caption":"Everything You Need to Know About Acute Kidney Injury\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30819"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30819\/revisions"}],"predecessor-version":[{"id":30825,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30819\/revisions\/30825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30820"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30819"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30819"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}